Michael Schlichting

8.5k citations
44 papers · 6.2k · 4 hit papers · h-index 16

Impact in

  • Oncology top 0.2%
    • Colorectal Cancer Treatments and Studies
    • Cancer Immunotherapy and Biomarkers
    • Cancer Treatment and Pharmacology
  • Hepatology top 0.5%
    • Hepatocellular Carcinoma Treatment and Prognosis

Papers in

    • Colorectal Cancer Treatments and Studies 14
    • Polyomavirus and related diseases 7
    • Cancer Immunotherapy and Biomarkers 4
    • Cancer Treatment and Pharmacology 3
    • Bladder and Urothelial Cancer Treatments 4

Michael Schlichting

42 papers receiving 6.1k citations

Michael Schlichting's Hit Papers

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study 2017 · 469 citations
4690+5+11Years since publication50010001.5k2.0k2.5k

Peers

Michael Schlichting
Comparison fields: 5 of 94
  • Oncology 4.3k
  • Hepatology 936
  • Pathology and Forensic Medicine 1.0k
  • Cancer Research 766
  • Pulmonary and Respiratory Medicine 1.3k
Replace Claus-Henning Köhne with:
Claus-Henning Köhne Germany
Chiara Cremolini Italy
Allen Lee Cohn United States
Alain Hendlisz Belgium
Angela Zubel Germany
Rafael G. Amado United States
Gianluca Masi Italy
Kelly S. Oliner United States
Lawrence S. Blaszkowsky United States
Christiane Langer United States
Michael Schlichting relative to Claus-Henning Köhne Germany Claus-Henning Köhne's profile →
Citations per field
00.5×1.6×
Claus-Henning Köhne · 1×
Citations per year

Countries citing papers authored by Michael Schlichting

Since Specialization
Citations

This map shows the geographic impact of Michael Schlichting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Schlichting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Schlichting more than expected).

Fields of papers citing papers by Michael Schlichting

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Schlichting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Schlichting. The network helps show where Michael Schlichting may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Schlichting, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Schlichting Line = papers co-authored together Michael Schlichting links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Hit paper breakdown →
20092914
2
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Hit paper breakdown →
20111445
3
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Hit paper breakdown →
2017469
4
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
Hit paper breakdown →
2012447
5 2012287
6 2013170
7 201294
8 202192
9 201650
10 202026
11 201623
12 201321
13 201720
14 202218
15 201917
16 201915
17 202014
18 201713
19 201711
20 20229

About Michael Schlichting

Michael Schlichting is a scholar working on Oncology, Surgery, Cancer Research, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 44 papers that have together received 6.2k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (14 papers), Polyomavirus and related diseases (7 papers), Cancer Genomics and Diagnostics (6 papers), Cancer Immunotherapy and Biomarkers (4 papers), Bladder and Urothelial Cancer Treatments (4 papers), Lung Cancer Treatments and Mutations (4 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Cancer Treatment and Pharmacology (3 papers). The work is most often cited by research in Oncology (4.3k citations), Hepatology (936 citations), Pathology and Forensic Medicine (1.0k citations), Cancer Research (766 citations) and Pulmonary and Respiratory Medicine (1.3k citations). Michael Schlichting has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Eric Van Cutsem, Philippe Rougier, Gunnar Folprecht, Claus-Henning Köhne, Ilhan Celik, Sabine Tejpar, Anatoly Makhson, Geert D’Haens, Johannes Nippgen and Christopher Stroh. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Value in Health, Future Oncology and Health and Quality of Life Outcomes.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact